Immunhistologische Untersuchungen an primären Melanomen und deren Metastasen mit SM5-1, einem neuen monoklonalen AntikörperSusanne Reinke1.11.11.221.331.41.541.656781.791.7.110112.12133.143.13.23.3153.4163.5173.63.7183.7.119624#2263.7.2203.83.921224.234.1244.2254.326274.4284.52930623#416624#2214.6314.7324.8334.934354.10365.375.1385.239405.341425.4435.5445.65.7456.46 7. LiteraturverzeichnisVIIIIXXXIXIIXIIIXIV 8. PublikationXV 9. Eidesstattliche ErklärungXVI 10. DanksagungXVIIdeInhaltsverzeichnisHilfe 7. Literaturverzeichnis Pschyrembel Klinisches Wörterbuch. Melanom, malignes; Melanozyten. 259. Aufl., Walter de Gruyter Verlag

Berlin - New York

, 2002:1043-1046 Riede U-N, Schaefer H-E. Allgemeine und spezielle Pathologie. 4. Aufl., aktualisierter Nachdruck, Georg Thieme Verlag

Stuttgart - New York

, 2001:944-946. Sebastian G, Stein A. Das maligne Melanom der Haut. UNI-MED Verlag,

Bremen

, 2000:11-126. Reed RJ, Martin P: Variants of melanoma. Semin Cutan Med Surg. 1997;16:137-158. Perniciaro C: Dermatopathological variants of malignant melanomas. Mayo Clin Proc. 1997;72:273-279. Clark WH Jr, From L, Bernardino EA, et al.: The histogenesis and biologic behavior of primary human malignant melanomas of the skin. Cancer Res. 1969;29(3): 705-727. Jung EG. Dermatologie. 4. Aufl., Hippokrates Verlag,

Stuttgart

, 1998:228-238 Su WP: Malignant melanoma: basic approach to clinicopathologic correlation. Mayo Clin Proc. 1997;72(3):267-272. Porras BH, Cockerell CJ: Cutaneous malignant melanoma: classification and clinical diagnosis. Semin Cutan Med Surg. 1997;16(2): 88-96. Sahel JA, Albert DM: Intraocular melanomas. Cancer Treat Res. 1993;65:161-199. Holman CDJ, Mulroney CD, Armstrong BK: Epidemiology of preinvasive and invasive malignant melanoma in Western Australia. Int J Cancer. 1980;25:317-323. Robertson I, Cook MG, Dymock RB, Orell SR: Cutaneous malignant melanoma in South Australia. The main feature. Med J Australia. 1981;2:92-94. Schreiber MM, Bozzo PD, Moon E: Malignant melanoma in Southern Arizona. Increasing incidence and sunlight as an etiolgic factor. Arch Dermatol. 1981;117:6-11. Little JH, Holt J, Davis N: Changing epidemiology of malignant melanoma in Queensland. Med J Australia. 1980;26(1): 66-69. Rigel DS, Kopf AW, Friedman RJ: The rate of malignant melanoma in the United States: Are we making an impact? J Am Acad Dermatol. 1987;17(6):1050-1053. Brobeil A, Rapaport D, Wells K et al: Multiple primary melanomas: implications for screening and follow-up programs for melanoma. Ann Surg Oncol. 1997;4(1): 19-23. Balch CM, Buzaid AC, Soong SJ et al: Final Version of the American Joint Committee on Cancer Staging System for Cutaneous Melanoma. J Clin Oncol. 2001;19(16):3635-3648. Moehrle M, Blum A, Rassner G et al: Lymph node metastases of cutaneous melanoma: diagnosis by B-scan and color Doppler sonography. J Am Acad Dermatol. 1999;41(5): 703-709. Zitelli JA, Brown CD, Hanusa BH: Surgical margins for excision of primary cutaneous melanoma. J Am Acad Dermatol. 1997;37(3): 422-429. Orchard G, Wilson JE: Immunocytochemistry in the diagnosis of malignant melanoma. Br J Biomed Sci. 1994;51(1):44-56. van der Bruggen P, Traversari C, Chomez P et al: A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science. 1991;254(5038):1643-1647. Cochran AJ, Wen DR, Herschman HR et al: Detection of S100 protein as an aid to the identification of melanocytic tumors. Int J Cancer. 1982;30:295-297. Adema GJ, de-Boer AJ, Vogel AM et al: Molecular characterization of the melanocyte lineage-specific antigen gp100. J Biol Chem. 1994;269:20126-20133. Chen YT, Stockert E, Tsang S et al: Immunophenotyping of melanomas for tyrosinase: implications for vaccine development. Proc Natl Acad Sci.1995;92:8125-8129. Coulie PG, Brichard V, Van Pel A et al: A new gene coding for a differentiation antigen recognized by autologous cytolytic T-lymphocytes on HLA-A2 melanomas. J Exp Med. 1994;180(1): 35-42. Gaugler B, Van den Eynde B, van der Bruggen P et al: Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytoloytic T lymphocytes. J Exp Med. 1994;179(3):921-930. Gown AM, Vogel AM, Hoak D et al: Monoclonal antibodies specific for melanocytic tumors distinguish subpopulations of melanocytes. Am J Pathol. 1986;123:195-203. Jungbluth AA, Busam KJ, Gerald WL et al: A103: An anti-melan-a monoclonal antibody for the detection of malignant melanoma in paraffin-embedded tissues. Am J Surg Pathol. 1998;22:595-602. Chen YT, Stockert E, Chen Y et al: Identification of the MAGE-1 gene product by monoclonal and polyclonal antibodies. Proc natl Acad Sci. 1994;91:1004-1008. Kocher T, Schultz-Thater E, Gudat F et al: Identification and intracellular location of MAGE-3 gene product. Cancer Res. 1995;55(11):2236-2239. Jungbluth AA, Iversen K, Coplan K et al: T311 - an anti-tyrosinase monoclonal antibody for the detection of melanocytic lesions in paraffin embedded tissues. Pathol Res Pract. 2000;196:235-242. Brasseur F, Rimoldi D, Lienard D et al: Expression of MAGE genes in primary and metastatic cutaneous melanoma. Int J Cancer. 1995;63(3):375-380. Ordonez NG, Ji XL, Hickey RC: Comparison of HMB-45 monoclonal antibody and S100 protein in the immunhistochemical diagnosis of melanoma. Am J Clin Pathol. 1988;90:385-390. Wick MR, Swanson PE, Rocamora A: Recognizion of malignant melanoma by monoclonal antibody HMB-45. An immunhistological study of 200 paraffin-embedded cutaneous tumors. J Cutan Pathol. 1988;15:201-207. Esclamado RM, Gown AM, Vogel AM: Unique proteins defined by monoclonal antibodies specific for melanocytic tumors distinguish subpopulations of melanocytes. Am J Pathol. 1986;123:195-203. Smoller BR, McNutt NS, Hsu A: HMB-45 recognizes stimulated melanocytes. J Cutan Pathol. 1989;16:49-53. Smoller BR, McNutt NS, Hsu A: HMB-45 staining of dysplastic nevi. Support for a spectrum of progression toward melanoma. Am J Pathol. 1989;13:680-684. Sun J, Morton TH jr, Gown AM: Antibody HMB-45 identifies the cells of blue nevi. An immunhistochemical study on paraffin sections. Am J Surg Pathol. 1990;14:748-751. Herrera GA, Hancock C: Specifity of antibody HMB-45. Arch Pathol Lab Med. 1992;116:900-901. Argenyi ZB, Cain C, Bromley C et al: S100 protein-negative malignant melanoma: fact or fiction? A light-microscopic and immunohistochemical study. Am J Dermatopathol. 1994;16:233-240. Gatter KC, Ralfkiaer E, Skinner J et al: An immunocytochemical study of malignant melanoma and its differential diagnosis from other malignant tumors. J Clin Pathol. 1985;38:1353-1357. Hachisuka H, Sakamoto F, Nomura H etal: Immunohistochemical study of S100 protein and neuron specific enolase (NSE) in melanocytes and the related tumors. Acta Histochem. 1986;80:215-223. Kindblom LG, Lodding P, Rosengren L et al: S100 protein in melanocytic tumors. An immunohistochemical investigation of benign and malignant melanocytic tumors and metastases of malignant melanoma and a characterization of the antigen in comparison to human brain.Acta Pathol Microbiol Immunol Scand. 1984;92:219-230. Stefansson K, Wollmann RL, Moore BW et al: S100 protein in human chondrocytes. Nature. 1982;295:63-64. Stefansson K, Wollmann RL, Moore BW: Distribution of S100 protein outside the central nervous system. Brain Res. 1982;234:309-317. Tabuchi K, Moriya Y, Furuta T et al: S100 protein in human glial tumors. Qualitative and quantitative studies. Acta Neurochir Wien. 1982;65:239-251. Vanstapel MJ, Gatter KC, de Wolf Peeters C et al: New sites of human S100 immunoreactivity detected with monoclonal antibodies. Am J Clin Pathol. 1986;85:160-168. Drier JK, Swanson PE, Cherwitz DL et al: S100 protein immunoreactivity in poorly differentiated carcinomas. Immunohistochemical comparison with malignant melanoma. Arch Pathol Lab Med. 1987;11:447-452. Hofbauer GF, Kamarashev J, Geertsen R et al: Melan-A/MART-1 immunoreactivity in formalin-fixed paraffin-embedded primary and metastatic melanoma: frequency and distribution. Melanoma Res. 1998;84:337-343. Kaufmann O, Koch S, Burghardt J et al: Tyrosinase, melan-A and KBA62 as markers for the immunohistochemical identification of metastatic amelanotic melanomas on paraffin sections. Mod Pathol. 1998;11(8):740-746. Busam KJ, Chen YT, Old LJ et al: Expression of melan-A (MART1) in benign melanocytic nevi and primary cutaneous malignant melanoma. Am J Surg Pathol. 1998;22:976-982. Busam KL, Iversen K, Coplan KA et al: Immunoreactivity for A103, an antibody to melan-A (Mart-1), in adrenocortical and other steroid tumors. Am J Surg Pathol. 1998;22(1):57-63. Hofbauer GF, Kamarashev J, Geertsen R et al: Tyrosinase immunoreactivity in formalin-fixed, paraffin-embedded primary and metastatic melanoma: frequency and distribution. J Cutan Pathol. 1998;25(4):204-209. Basarab T, Picard JK, Simpson E et al: Melanoma antigen-encoding gene expression in melanocytic naevi and cutaneous malignant melanomas. Br J Dermatol. 1999;140(1):106-108. Hofbauer GF, Schaefer C, Noppen C et al: MAGE-3 immunoreactivity in formalin-fixed, paraffin-embedded primary and metastytic melanoma: frequency and distribution. Am J Pathol. 1997;151:1549-1553. Gudat F, Zuber M, Durmuller U et al: The tumour associated antigen MAGE-1 is detectable in formalin-fixed paraffin sections of malignant melanoma. Virchows Arch. 1996;429:77-81. Boenisch T (Hrsg.). Handbuch Immunchemische Färbemethoden. 3. Aufl., DakoCytomation Corporation, Carpinteria, DakoCytomation GmbH,

Hamburg

, 2003:5-79. Shi SR, Key ME, Kalra KL: Antigen retrieval in formalin-fixed, paraffin-embedded tissues: an enhancement method for immunohistochemical staining based on microwave oven heating of tissue sections. J Histochem Cytochem. 1991;39:741-748. Guo Y, Ma J, Wang J et al: Inhibition of human melanoma growth and metastasis in vivo by anti-CD44 monoclonal antibody. Cancer Res. 1994;54:1561-1565. Köhler G, Milstein C: Derivation of specific antibody producing tissue culture and tumor lines by cell fusion. Eur J Immunol. 1976;6:511-519. Sternberger LA, Hardy PH Jr, Cuculis JJ et al: The unlabeled antibody enzyme method of immunohistochemistry: preparation and properties of soluble antigen-antibody complex (horseradish peroxidase-antihorseradish peroxidase) and its use in identification of spirochetes. J Histochem Cytochem. 1970;18:315-313. Hsu SM, Raine L, Fanger H: Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures. J Histochem Cytochem. 1981;29:577-580. Colombari R, Bonetti F, Zamboni G et al: Distribution of melanoma specific antibody (HMB-45) in benign and malignant melanocytic tumours. Virchows Archiv A Pathol Anat. 1988;413:17-24. Mirecka J, Korabiowska M, Schauer A: Comparative distribution of S-100 protein and antigen HMB-45 in various types of melanomas and naevi. Pol J Pathol. 1995;46:167-172. Shah IA, Gani OS, Wheler L: Comparative immunoreactivity of CD-68 and HMB-45 in malignant melanoma, neural tumors and nevi. Pathol Res Pact. 1997;193:497-502. Swerdlow AJ, Storm HH, Sasieni PD: Risks of second primary malignancy in patients with cutaneous and ocular melanoma in Denmark, 1943-1989. Int J Cancer. 1995;61:773-779. Mottolese M, Venturo I, Benevolo M et al: Immunocytochemical diagnosis of amelanotic metastatic melanoma using monoclonal antibodies HMB-45 and Ep1-3. Melanoma Res. 1994;4:53-58. Adema GJ,Boer AJ, Van’t Hullenaar R et al: Melanocyte lineage-specific antigens recognized by monoclonal antibodies NKI-beteb, HMB-50, and HMB-45 are encoded by a single cDNA. Am J Pathol. 1993;143:1579-1585. Cormier JN, Abati A, Fetsch P et al: Comparative analysis of the in vivo expression of tyrosinase, MART-1/Melan-A, and gp100 in metastatic melanoma lesions: implications for immunotherapy. J Immunother. 1998;21:27-31. Fetsch PA, Riker AI, Marincola FM et al: Tyrosinase immunoreactivity in fine-needle aspiration samples of metastatic malignant melanoma. Cancer. 2000;90:252-257. Jäger E, Ringhoffer M, Altmannsberger M et al: Immunoselection in vivo: independent loss of MHC class I and melanocyte differentiation antigen expression in metastatic melanoma. Int J Cancer. 1997;71:142-147. Kageshita T, Kawakami Y, Hirai S et al: Differential expression of MART-1 in primary and metastatic melanoma lesions. J Immunother. 1997;20:460-465. Blessing K, Sanders DS, Grant JJ: Comparison of immunohistochemical staining of the novel antibody melan-A with S100 protein and HMB-45 in malignant melanoma and melanoma variants. Histopathology. 1998;32:139-146. De Vries TJ, Fourkour A, Wobbes T et al: Heterogeneous expression of immunotherapy candidate proteins gp100, MART-1, and tyrosinase in human melanoma cell lines and in humanmelanocytic lesions. Cancer Res. 1997;57:3223-3229. Slingluff CL, Colella TA, Thompson L et al: Melanomas with concordant loss of multiple melanocytic differentiation proteins: immune escape that may be overcome by targeting unique or undefined antigens. Cancer Immunother. 2000;48:661-672. De Vries TJ, Smeets M, de Graad R et al: Expression of gp100, MART-1, tyrosinase, and S100 in paraffin-embedded primary melanomas and locoregional, lymph node, and visceral metastases: implications for diagnosis and immunotherapy. A study conducted by the EORTC Melanoma Cooperative Group. J Pathol. 2001;193:13-20.